{
  "protocolSection": {
    "identificationModule": null,
    "descriptionModule": null,
    "conditionsModule": null,
    "designModule": null,
    "armsInterventionsModule": null,
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Freedom from atrial arrhythmia lasting ≥30 seconds",
          "description": "Any documented atrial arrhythmia (AF, AT, or atrial flutter) lasting for ≥30 seconds consecutively recorded on the Holter monitor, 12-lead ECG, pacemaker, loop recorder, and AliveCor Kardia recorded ECG after a 90-day blanking period.",
          "timeFrame": "12 months after a 90-day blanking period"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Repeat ablation for atrial arrhythmia",
          "description": "Repeat ablation for AF/AT/atrial flutter after a 90-day blanking period",
          "timeFrame": "12 months after a 90-day blanking period"
        },
        {
          "measure": "Mortality",
          "description": "All-cause mortality during the follow-up period",
          "timeFrame": "12 months"
        },
        {
          "measure": "Procedure-related complications",
          "description": "Any significant complications related to the procedure (bleeding, thrombosis, phrenic nerve palsy, and cardiac tamponade) requiring intervention",
          "timeFrame": "12 months"
        },
        {
          "measure": "Reduction in antiarrhythmic drug usage",
          "description": "Change in the proportion of patients using antiarrhythmic drugs postablation compared to baseline",
          "timeFrame": "12 months after a 90-day blanking period"
        }
      ]
    },
    "eligibilityModule": null
  }
}